0
0
10/23/23 at 1:07am
Organization
OncLive
Author
Ryan Scott
34 words
0
Comments
Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.
You are the first to view
https://www.onclive.com/view/trastuzumab-deruxtecan-has-clinically-meaningful-activity-in-solid-tumors-harboring-her2-mutations
Create an account
or login to join the discussion